Transcription factors in autoimmune diseases

被引：28

作者：

Eggert, M

Klüter, A

Zettl, UK

Neeck, G

机构：

[1] Rostock Clin S, Dept Internal Med, D-18059 Rostock, Germany

[2] Rostock Clin S, Ctr Rheumatol, D-18059 Rostock, Germany

[3] Univ Rostock, Dept Neurol, D-18147 Rostock, Germany

来源：

CURRENT PHARMACEUTICAL DESIGN | 2004年 / 10卷 / 23期

关键词：

diabetes type 1; glucocorticoids; multiple sclerosis; NF-kappa B; rheumatoid arthritis; transcription factors; therapy;

D O I：

10.2174/1381612043383593

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The analysis of the molecular basis of autoimmune diseases is currently under intense investigation. The identification of novel mechanisms underlying the pathogenesis of these diseases generates the possibility for the development of new therapeutic agents. In this review we summarize the results leading to novel insights concerning the molecular processes involved in the pathogenesis of rheumatoid arthritis, systemic lupus erythematodes, multiple sclerosis and diabetes type 1. We focus on the role of transcription factors such as nuclear factor kappa B, activator protein 1, peroxisome proliferator-activated receptor, vitamin D receptor and the glucocorticoid receptor that mediate pro- and anti-inflammatory effects and therefore represent direct or indirect targets for therapeutic intervention.

引用

收藏

页码：2787 / 2796

页数：10

相关论文

共 121 条

[11] Hepatocyte nuclear factor-1α gene mutations and diabetes in Norway [J].

Bjorkhaug, L ;

Sagen, JV ;

Thorsby, P ;

Sovik, O ;

Molven, A ;

Njolstad, PR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) :920-931

[12]

Bläss S, 1999, ARTHRITIS RHEUM, V42, P2499, DOI 10.1002/1529-0131(199912)42:12<2499::AID-ANR1>3.0.CO

[13]

2-R

[14]

Blevins G, 2003, SEMIN NEUROL, V23, P147

[15] New approaches to investigating heterogeneity in complex traits [J].

Bomprezzi, R ;

Kovanen, PE ;

Martin, R .

JOURNAL OF MEDICAL GENETICS, 2003, 40 (08) :553-559

[16] Nuclear factor κB activity is essential for matrix metalloproteinase-1 and-3 upregulation in rabbit dermal fibroblasts [J].

Bond, M ;

Baker, AH ;

Newby, AC .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 264 (02) :561-567

[17] Activation of NF-κB and c-jun transcription factors in multiple sclerosis lesions -: Implications for oligodendrocyte pathology [J].

Bonetti, B ;

Stegagno, C ;

Cannella, B ;

Rizzuto, N ;

Moretto, G ;

Raine, CS .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (05) :1433-1438

[18] Anti-inflammatory action of type I interferons deduced from mice expressing interferon β [J].

Boscá, L ;

Bodelón, OG ;

Hortelano, S ;

Casellas, A ;

Bosch, F .

GENE THERAPY, 2000, 7 (10) :817-825

[19] Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].

Brandt, J ;

Khariouzov, A ;

Listing, J ;

Haibel, H ;

Sörensen, H ;

Grassnickel, L ;

Rudwaleit, M ;

Sieper, J ;

Braun, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675

[20] Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Burmester, G ;

Golder, W ;

Gromnica-Ihle, E ;

Kellner, H ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Reddig, J ;

Sieper, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233

← 1 2 3 4 5 6 7 8 9 10 →